Acton, MA, United States of America

Yaping Wang


Average Co-Inventor Count = 12.9

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Naperville, IL (US) (2003)
  • Acton, MA (US) (2006)

Company Filing History:


Years Active: 2003-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yaping Wang: Innovator in Pharmaceutical Compounds

Introduction

Yaping Wang is a prominent inventor based in Acton, MA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of integrin receptor antagonists. With a total of 2 patents, her work has the potential to impact various therapeutic areas.

Latest Patents

Yaping Wang's latest patents include innovative compounds that serve as integrin receptor antagonists. One of her notable inventions is related to thiazole compounds, which are designed to selectively inhibit or antagonize the αβ and/or the αβ integrin without significantly affecting the αβ integrin. This specificity is crucial for developing targeted therapies. Another patent focuses on gem-substituted αvβ3 antagonists, further showcasing her expertise in creating compounds that can modulate integrin activity.

Career Highlights

Yaping Wang is currently associated with Pharmacia Corporation, where she continues to advance her research in pharmaceutical innovations. Her work has garnered attention for its potential applications in treating various diseases, highlighting her role as a key player in the pharmaceutical industry.

Collaborations

Yaping has collaborated with notable colleagues, including Thomas Dale Penning and Mark Andrew Russell. These partnerships have contributed to her success and the advancement of her research projects.

Conclusion

Yaping Wang's contributions to the field of pharmaceuticals through her innovative patents demonstrate her commitment to advancing medical science. Her work in developing integrin receptor antagonists is paving the way for new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…